We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

9660:HKEXHorizon Robotics Class B Analysis

Data as of 2026-07-07 - not real-time

HK$4.41

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Horizon Robotics is trading at HK$4.41, just above its 20‑day SMA of 4.37 but well below the 50‑day and 200‑day averages, indicating a short‑term bounce within a longer‑term bearish backdrop. The RSI of 43.5 suggests neutral momentum, while the MACD histogram turning positive signals a potential bullish reversal, supported by an increasing volume trend. Market sentiment is extremely optimistic, reflected by a Fear‑Greed Index of 93.13 (Extreme Greed) and an implied upside of roughly 148% to the consensus target of around HK$11. Despite this, the company carries a heavy debt load (Debt‑to‑Equity >120%) and reports negative earnings, operating margins and cash flows, which tempers the enthusiasm.
Fundamentally, Horizon Robotics holds a solid cash buffer of over HK$20 bn against HK$15.5 bn of debt, but its negative EBITDA, ROE and profit margins raise concerns about near‑term profitability. The valuation metrics are stretched – a price‑to‑book of 4.42 and price‑to‑sales of 17.1 – while the P/E is negative, making traditional earnings‑based valuation difficult. Analyst consensus is strongly positive ("strong_buy" from 20 analysts), yet the financial profile suggests the stock is priced for future growth rather than current cash generation.
Volatility is high at over 74% on a 30‑day basis and beta is modest at 0.57, indicating price swings but limited correlation with broader market moves. Combined with sector‑specific risks in Chinese AI and automotive regulation, the overall risk profile is elevated. The technical setup points to a short‑term buying opportunity, but the fundamental weaknesses advise caution for longer horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD histogram with rising volume
  • Price holding above near‑term support
  • Extreme greed sentiment boosting demand

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst consensus of strong buy
  • Large upside to consensus target price
  • Strong cash position offsetting debt

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Need for sustainable profitability
  • Exposure to Chinese regulatory environment
  • High leverage relative to equity

Key Metrics & Analysis

Financial Health

Revenue Growth51.20%
Profit Margin-278.56%
P/E Ratio-64.5
ROE-85.27%
ROA-9.21%
Debt/Equity123.05
P/B Ratio4.4
Op. Cash FlowHK$-2106051968
Free Cash FlowHK$-2224440832
Industry P/E36.6

Technical Analysis

TrendBearish
RSI43.5
SupportHK$3.60
ResistanceHK$5.13
MA 20HK$4.37
MA 50HK$5.60
MA 200HK$7.77
MACDBullish
VolumeIncreasing
Fear & Greed Index93.13

Valuation

Target PriceHK$10.98
Upside/Downside148.88%
GradeFair
TypeGrowth

Risk Assessment

Beta0.57
Volatility74.59%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.